Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice

PLoS Neglected Tropical Diseases

Volumn 4, Issue 8, 2010, Pages

  Gupta, Shivali ^a   Garg, Nisha Jain ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; INTERLEUKIN 12; RECOMBINANT PROTEIN; TRYPANOSOMA CRUZI VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; PARASITE ANTIGEN; PROTOZOAL VACCINE; PROTOZOON ANTIBODY; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART MUSCLE; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPATHOLOGY; INFECTION PREVENTION; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLASMID; PROTECTION; PROTEIN EXPRESSION; SKELETAL MUSCLE; T LYMPHOCYTE ACTIVATION; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; ANIMAL; BLOOD; C57BL MOUSE; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; METHODOLOGY; PATHOLOGY; SECRETION; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHAGAS DISEASE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNIZATION, SECONDARY; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; MYOCARDIUM; PLASMIDS; PROTOZOAN VACCINES; TRYPANOSOMA CRUZI; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 78149263261     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000797     Document Type: Article

References (55)

1. Schofield CJ, Jannin J, Salvatella R (2006) The future of Chagas disease control. Trends Parasitol 22: 583-588.
2. Schmunis GA, Yadon ZE (2010) Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop 115: 14-21.
3. Franchin G, Pereira-Chioccola VL, Schenkman S, Rodrigues MM (1997) Passive transfer of a monoclonal antibody specific for a sialic acid-dependent epitope on the surface of Trypanosoma cruzi trypomastigotes reduces infection in mice. Infect Immun 65: 2548-2554.
4. Krautz GM, Kissinger JC, Krettli AU (2000) The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol Today 16: 31-34.
5. Garg N, Tarleton RL (2002) Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70: 5547-5555.
6. Pereira-Chioccola VL, Costa F, Ribeirao M, Soares IS, Arena F, et al. (1999) Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein. Parasite Immunol 21: 103-110.
7. Ribeirao M, Pereira-Chioccola VL, Renia L, Augusto Fragata Filho A, Schenkman S, et al. (2000) Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase. Parasite Immunol 22: 49-53.
8. Garg N, Nunes MP, Tarleton RL (1997) Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway. J Immunol 158: 3293-3302.
9. Santori FR, Paranhos-Bacalla GS, Franco DASJ, Yamauchi LM, Araya JE, et al. (1996) A recombinant protein based on the Trypanosoma cruzi metacyclic trypomastigote 82-kilodalton antigen that induces and effective immune response to acute infection. Infect Immun 64: 1093-1099.
10. Sepulveda P, Hontebeyrie M, Liegeard P, Mascilli A, Norris KA (2000) DNABased immunization with trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against trypanosoma cruzi infection. Infect Immun 68: 4986-4991.
11. Planelles L, Thomas MC, Alonso C, Lopez MC (2001) DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun 69: 6558-6563.
12. Schnapp AR, Eickhoff CS, Sizemore D, Curtiss R, 3rd, Hoft DF (2002) Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun 70: 5065-5074.
13. Bhatia V, Garg NJ (2008) Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol 15: 1158-1164.
14. Bhatia V, Garg N (2005) Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines 4: 867-880.
15. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV (2007) Pathogenesis of chronic Chagas heart disease. Circulation 115: 1109-1123.
16. Rodrigues MM, de Alencar BC, Claser C, Tzelepis F, Silveira EL, et al. (2009) Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice. Mem Inst Oswaldo Cruz 104: 281-287.
17. Scott MT, Neal RA, Woods NC (1985) Immunization of marmosets with Trypanosoma cruzi cell surface glycoprotein (GP90). Trans R Soc Trop Med Hyg 79: 451-454.
18. Laderach D, Cerban F, Motran C, Vottero de Cima E, Gea S (1996) Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII). Int J Parasitol 26: 1249-1254.
19. Frank FM, Petray PB, Cazorla SI, Munoz MC, Corral RS, et al. (2003) Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 22: 77-86.
20. Bhatia V, Wen JJ, Zacks MA, Garg, NJ (2009) American trypanosomiasis and perspectives on vaccine development. In: Stanberry LR, Barrett AD, eds. Vaccines for Biodefense and Emerging and Neglected Diseases Academic Press NY. pp 1407-1434.
21. Cazorla SI, Becker PD, Frank FM, Ebensen T, Sartori MJ, et al. (2008) Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun 76: 324-333.
22. Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, et al. (2005) Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 73: 7356-7365.
23. Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, et al. (2006) Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 17: 898-908.
24. de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, et al. (2009) Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 77: 4383-4395.
25. Vasconcelos JR, Boscardin SB, Hiyane MI, Kinoshita SS, Fujimura AE, et al. (2003) A DNA-priming protein-boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain. Immunol Cell Biol 81: 121-129.
26. Bhatia V, Sinha M, Luxon B, Garg N (2004) Utility of Trypanosoma cruzi sequence database for the identification of potential vaccine candidates: In silico and in vitro screening. Infect Immun 72: 6245-6254.
27. Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175: 633-639.
28. Ivory C, Chadee K (2004) DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther 2: 17.
29. Scharpe J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, et al. (2009) Immunogenicity of a standard trivalent influenza vaccine in patients on longterm hemodialysis: an open-label trial. Am J Kidney Dis 54: 77-85.
30. Zeng R, Zhang Z, Mei X, Gong W, Wei L (2008) Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice. Biochem Biophys Res Commun 377: 495-499.
31. Moore AC, Hill AV (2004) Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199: 126-143.
32. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, et al. (2006) Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24: 4554-4561.
33. Campos-Neto A, Soong L, Cordova JL, Sant'Angelo D, Skeiky YA, et al. (1995) Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J Exp Med 182: 1423-1433.
34. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, et al. (2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309: 409-415.
35. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
36. Garg N, Popov VL, Papaconstantinou J (2003) Profiling gene transcription reveals a deficiency of mitochondrial oxidative phosphorylation in Trypanosoma cruzi-infected murine hearts: implications in chagasic myocarditis development. Biochim Biophys Acta 1638: 106-120.
37. Garg N, Gerstner A, Bhatia V, DeFord J, Papaconstantinou J (2004) Gene expression analysis in mitochondria from chagasic mice: alterations in specific metabolic pathways. Biochem J 381: 743-752.
38. McShane H, Hill A (2005) Prime-boost immunisation strategies for tuberculosis. Microbes Infect 7: 962-967.
39. Hall SS (1995) IL-12 at the crossroads [news] [see comments]. Science 268: 1432-1434.
40. Lin R, Tarr PE, Jones TC (1995) Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin Infect Dis 21: 1439-1449.
41. Brodskyn CI, Silva AM, Takehara HA, Mota I (1989) IgG subclasses responsible for immune clearance in mice infected with Trypanosoma cruzi. Immunol Cell Biol 67(Pt 6): 343-348.
42. Powell MR, Wassom DL (1993) Host genetics and resistance to acute Trypanosoma cruzi infection in mice. I. Antibody isotype profiles. Parasite Immunol 15: 215-221.
43. Costa F, Franchin G, Pereira-Chioccola VL, Ribeirao M, Schenkman S, et al. (1998) Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine 16: 768-774.
44. Guedes PM, Veloso VM, Gollob KJ, Afonso LC, Caldas IS, et al. (2008) IgG isotype profile is correlated with cardiomegaly in Beagle dogs infected with distinct Trypanosoma cruzi strains. Vet Immunol Immunopathol 124: 163-168.
45. Zacks MA, Wen JJ, Vyatkina G, Bhatia V, Garg N (2005) An overview of chagasic cardiomyopathy: pathogenic importance of oxidative stress. An Acad Bras Cienc 77: 695-715.
46. Gazzinelli RT, Oswald IP, Hieny S, James SL, Sher A (1992) The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur J Immunol 22: 2501-2506.
47. Brener Z, Gazzinelli RT (1997) Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 114: 103-110.
48. Rottenberg ME, Bakhiet M, Olsson T, Kristensson K, Mak T, et al. (1993) Differential susceptibilities of mice genomically deleted of CD4 and CD8 to infections with Trypanosoma cruzi or Trypanosoma brucei. Infect Immun 61: 5129-5133.
49. Reed SG (1988) In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol 140: 4342-4347.
50. Barbosa de Oliveira LC, Curotto de Lafaille MA, Collet de Araujo Lima GM, de Almeida Abrahamsohn I (1996) Antigen-specific IL-4- and IL-10-secreting CD4+ lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection. Cell Immunol 170: 41-53.
51. Torrico F, Heremans H, Rivera MT, Van Marck E, Billiau A, et al. (1991) Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice. J Immunol 146: 3626-3632.
52. Hoft DF, Schnapp AR, Eickhoff CS, Roodman ST (2000) Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi. Infect Immun 68: 197-204.
53. Reis DD, Jones EM, Tostes S, Jr., Lopes ER, Gazzinelli G, et al. (1993) Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg 48: 637-644.
54. Correa-Oliveira R, Gomes J, Lemos EM, Cardoso GM, Reis DD, et al. (1999) The role of the immune response on the development of severe clinical forms of human Chagas disease. Mem Inst Oswaldo Cruz 94: 253-255.
55. Talvani A, Ribeiro CS, Aliberti JC, Michailowsky V, Santos PV, et al. (2000) Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi. Microbes Infect 2: 851-866.